Research and Clinical Trials

At this time, the APS Foundation of America does not fund research, however, we will do so in the near future.

The following organizations are currently doing research on APS or related diseases. We encourage anyone who qualifies to participate in these clinical studies. By doing so, you could potentially help APS patients in the future!

APS ACTION Hydroxychloroquine Study (1)

Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*

Contact:

Joann Vega
(212) 774-2795

aPL-positive patients with no history of thrombosis or other systemic autoimmune diseases are randomized to receive hydroxychloroquine or no treatment in addition to their standard regimen. The study involves 11 study visits and 10 phone visits over 5 years.

APS ACTION aPL/APS Registry (2)

Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*

Contact:

Joann Vega
(212) 774-2795

Any aPL-positive patient is included in this clinical database and repository. The study involves 11 study visits and 10 phone visits over 10 years.

Microbiome Study (3)

Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY

Contact:

Joann Vega
(212) 774-2795

aPL-positive patients who are not receiving immunosuppressive treatment is included in this study that seeks to find if any particular intestinal bacteria may trigger aPL production. Participation will involve 3 study visits over a period of 2 months

PROMISSE Study (4)

Principal Investigator:
Dr. Jane Salmon
Hospital for Special Surgery, New York, NY*

Contact:

Anasam Aslam
(212) 774-2115

Pregnant (6-11 weeks preferably, but can usually recruit up to 18 weeks), history of aPL positivity with or without SLE.

AXLN1007 in Antiphospholipid Syndrome (5)

Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*

Contact:

Joann Vega
(212) 774-2795

Study Title: An Open-Label Proof of Concept Phase IIa Trial of AXLN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
This is an open-label study where patients will receive 12 doses of study drug over 22 weeks for Non-criteria Manifestations of APS (low platelet count, skin ulcers or abnormal kidney function).

Navigate through Current Clinical Trials using the left and right arrows.

If You Have Antiphospholipid Syndrome (APS) And Lupus, You May Qualify For A Research Study

If You Have Antiphospholipid Syndrome (APS) And Lupus, You May Qualify For A Research Study

The Paisley Study is a research study that is evaluating an oral investigational drug for people with moderate to severe systemic lupus erythematosus (SLE). Qualified participants must be on stable anticoagulant therapy as long as APS is not the sole or predominant feature of their SLE.

Visit PaisleyStudy.com to learn more today.

Our Mission

Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.

This site complies with the HONcode standard for trustworthy health information: verify here.

Contact

APS Foundation of America, Inc.
P. O. Box 801
LaCrosse, WI 54602-0801

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.

Rare Diseases Clinical Research Network

Rare Disease Clinical Research Network

The Rare Diseases Clinical Research Network was created to facilitate collaboration among experts in many different types of rare diseases. Our goal is to contribute to the research and treatment of rare diseases by working together to identify biomarkers for disease risk, disease severity and activity, and clinical outcome, while also encouraging development of new approaches to diagnosis, prevention, and treatment.

For more information, visit rarediseasesnetwork.org.

Clinical Study: PROMISSE

NOW RECRUITING

Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE)

The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE.

More Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00198068

Contact:
Marta M. Guerra, MS
212-774-7361
guerram@hss.edu

Clinical Study: Genetic Risk Factors Associated With APS

NOW RECRUITING

Genetic Risk Factors Associated With Antiphospholipid Syndrome (APS)

Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body’s ability to perform normal blood clotting. Clinical problems associated with antiphospholipid antibodies include an increased risk for the formation of blood clots in the lungs or deep veins of the legs, stroke, heart attack, and recurrent miscarriages. It is possible that some people with APS have a genetic predisposition for developing the syndrome. This study will use a genetic strategy to identify potential inherited risk factors for the development of APS by recruiting people with APS who have family members also affected by the syndrome or by another autoimmune disorder, such as lupus or rheumatoid arthritis.

 

More Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00482794

 

Contact:
Thomas L. Ortel, MD, PhD
919-684-5350
thomas.ortel@duke.edu

APS ACTION

The primary mission of APS ACTION is to prevent, treat, and cure antiphospholipid antibody (aPL) associated clinical manifestations through high-quality, multicenter, and multidisciplinary clinical research. Their secondary mission is to refine and advance the definitions of aPL associated clinical manifestations through international collaboration and data sharing.

Their approach is simple: Members will work together to create a research alliance that will design and conduct clinical trials, and collect data via an international registry.

For more information, visit apsaction.org.

Our Mission

Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.

This site complies with the HONcode standard for trustworthy health information: verify here.

Contact

APS Foundation of America, Inc.
P. O. Box 801
LaCrosse, WI 54602-0801

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.